EIDD-1931, 15mg | antiviral therapy for feline infectious peritonitis

MolnuFIP™ EIDD-1931 is the newest antiviral therapy specifically formulated for the treatment of feline infectious peritonitis (FIP). Designed exclusively for veterinary use, MolnuFIP™ eliminates the need for human molnupiravir, offering a targeted, optimized approach for feline patients.
 
Each MolnuFIP™ capsule is precisely dosed based on a cat’s body weight and metabolic rate, ensuring accurate, consistent treatment with minimal variability.
 
Proven Efficacy
Clinical researches demonstrate that EIDD-1931 is 4.4 times more potent than human molnupiravir (EIDD-2801) and 7.3 times more potent than GS-441524, enabling faster recovery with fewer side effects.
 
Comprehensive FIP Coverage
Effective for both wet and dry FIP
Near-zero relapse rate
Optimized for feline metabolism
 
With MolnuFIP™ EIDD-1931, your cat receives a scientifically advanced, highly effective treatment—bringing them back to full health with precision, safety, and confidence.

Active Ingredient: EIDD-1931

Inactive Ingredient: Dibasic Calcium Phosphate, Magnesium Sterate

Form: Size 3 Capsules

Indications: Ideal for cats with effusive (wet) and non-effusive (dry) FIP symptoms such as fever, ascites, pleural effusion.

Specification: 60 capsules, each containing 15 mg of EIDD-1931

Dosage: 
1 capsule every 12 hours for cats below 2.5 kg of body weight.
2 capsules every 12 hours for cats between 2.5 kg to 5 kg of body weight.   
3 capsules every 12 hours for cat above 5 kg of body weight.

preferably on an empty stomach. If vomiting occurs within 30 minutes, administer another capsule.

Not Recommended For: Ocular or neurological cases, cats not feeding or defecating normally, and cats with a history of poor dietary absorption.

Length of Treatment: Up to 60 days or as recommended by a veterinarian.

Storage: Store in a dry, cool place away from sunlight.